farmacoproteomica

ABSTRACTS:
ROLE OF PHARMACOPROTEOMICS IN THE DEVELOPMENT OF PERSONALIZED MEDICINE.
PAPEL DE LA FARMACOPROTEOMICA EN EL DESARROLLO DE LA MEDICINA PERSONALIZADA.
http://www.ncbi.nlm.nih.gov/pubmed/15102547
Pharmacoproteomics is the use of proteomic technologies in drug discovery and development. Along with pharmacogenomics and pharmacogenetics, pharmacoproteomics will play an important role inthe development of personalized medicines in several ways. Proteomic technologies are contributing to molecular diagnostics, which is a basis of personalized medicine. Pharmacoproteomics is a more functional representation of patient-to-patient variation than that provided by genotyping. Proteomics-based characterization of multifactorial diseases may help to match a particular target-based therapyto a particular marker in a subgroup of patients. Individualized therapy may be based on differential protein expression rather than a genetic polymorphism. Finally, proteomic technologies would enable discovery and development of drugs suitable for personalized therapy. Protein chips will be used increasingly in clinical diagnostics in the next 5 years, particularly in the point-of-carediagnostics. This will facilitate the practice of personalized medicine in the clinic by the end of this decade.
Farmacoproteómica es el uso de tecnologías proteómicas en el descubrimiento y desarrollo de fármacos. Junto con la farmacogenómica y la farmacogenética, la farmacoproteómica jugará un papel importante en el desarrollo de medicamentos personalizados de varias maneras. Tecnologías proteómicasestán contribuyendo al diagnóstico molecular, que es una base de la medicina personalizada.
Farmacoproteómica es una representación más funcional de variación de paciente a paciente, que la proporcionada por la genotipificación. Proteómica basada en la caracterización de enfermedades multifactoriales puede ayudar a coincidir con una terapia particular basada en objetivo a un marcador particular en unsubgrupo de pacientes.
Terapia individualizada puede estar basada en la expresión diferencial de proteínas en lugar de un polimorfismo genético. Finalmente, las tecnologías proteómicas permitirían el descubrimiento y desarrollo de fármacos adecuados para la terapia personalizada. Chips de proteínas se utilizaran cada vez más en el diagnóstico clínico en los próximos 5 años, especialmente en eldiagnóstico de punto de atención. Esto facilitará la práctica de la medicina personalizada en la clínica a finales de esta década.





TECHNOLOGY INSIGHT: PHARMACOPROTEOMICS FOR CANCER—PROMISES OF PATIENT-TAILORED MEDICINE USING PROTEIN MICROARRAYS.

VISIÓN TECNOLOGICA: FARMACOPROTEOMICA PARA EL CANCER – PROMESAS DE MEDICINA PERSONALIZADA EN EL PACIENTE UTILIZANDO MICROARRAYS DE PROTEINAS.http://www.ncbi.nlm.nih.gov/pubmed/16683004
Patient-tailored medicine can be defined as the selection of specific therapeutics to treat disease in a particular individual based on genetic, genomic or proteomic information. While individualized treatments have been used in medicine for years, advances in cancer treatment have now generated a need to more precisely define and identify those patients whowill derive the most benefit from new-targeted agents. Cellular signaling pathways are a protein-based network, and the intended drug effect is to disrupt aberrant protein phosphorylation-based enzymatic activity and epigenetic phenomena. Pharmacoproteomics, or the tailoring of therapy based on proteomic knowledge, will begin to take a central role in this process. A new type of protein arrayplatform, the reverse-phase protein microarray, shows potential for providing detailed information about the state of the cellular 'circuitry' from small samples such as patient biopsy specimens. Measurements of hundreds of specific phosphorylated proteins that span large classes of important signaling pathways can be obtained at once from only a few thousand cells. Clinical implementation of these...